Improved Exercise Capacity

Significantly improved exercise capacity as monotherapy

Placebo-corrected increase in 6MWD at Week 12, measured 30 minutes after and immediately prior to inhalation^1,4

Peak = 30 minutes postinhalation; trough = immediately prior to inhalation

AIR Pivotal Trial: Randomized, double-blind, multicenter, placebo-controlled trial to evaluate the efficacy and safety of VENTAVIS^® (iloprost) Inhalation Solution monotherapy compared with placebo in the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) NYHA Functional Class III or IV (n=146). Clinical improvement is a combined endpoint defined as ≥10% increase in 6MWD, improvement in NYHA Functional Class, and absence of clinical deterioration or death.^1,4

At Week 12, there was a 40-meter difference between VENTAVIS and placebo (change from baseline in 6-minute walk distance measured 30 min post-inhalation; p <0.01)¹
When measured immediately prior to inhalation, the improvement compared to placebo was approximately 60% of the effect seen at 30 min post-inhalation¹